[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362407-105":3,"doc-detail-362407-en":81,"detail-sidebar-cat-0-en-105":115},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","high-grade-serous-ovarian-carcinoma-in-the-genomics-era-current-applications-challenges-and-future-directions","High-Grade Serous Ovarian Carcinoma in the Genomics Era - Current Applications, Challenges and Future Directions","","High-grade serous ovarian carcinoma (HGSOC) is marked by profound genomic instability and limited durable benefit from standard therapy, resulting in poor prognosis. Next-generation sequencing has clarified its molecular landscape, including recurrent TP53 mutations, homologous recombination defects, pathway changes, and epigenetic dysregulation. Genomic profiling supports classification and distinguishes HGSOC from other ovarian cancer subtypes, guiding platinum chemotherapy and PARP inhibitor use via homologous recombination deficiency. Multi-omics and emerging AI, CRISPR editing, neoantigen immunotherapy, and vaccination are promising despite intratumoural heterogeneity and limited dataset diversity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/high-grade-serous-ovarian-carcinoma-in-the-genomics-era-current-applications-challenges-and-future-directions/362407/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/high-grade-serous-ovarian-carcinoma-in-the-genomics-era-current-applications-challenges-and-future-directions/362407.png","ImageObject",300,407,{"name":42,"@type":43},"\tJames","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What makes high-grade serous ovarian carcinoma (HGSOC) clinically challenging?","Question",{"text":63,"@type":64},"HGSOC shows profound genomic instability and limited durable responses to standard therapy, which contributes to poor prognosis and high mortality.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do next-generation sequencing technologies improve understanding of HGSOC?",{"text":68,"@type":64},"They reveal a detailed molecular landscape, including recurrent TP53 mutations, homologous recombination defects, pathway alterations, and epigenetic dysregulation that support subtype classification.",{"name":70,"@type":61,"acceptedAnswer":71},"Which genomic features help guide treatment in HGSOC?",{"text":72,"@type":64},"Genomic profiling supports the use of platinum-based chemotherapy and PARP inhibitors, with homologous recombination deficiency functioning as a key vulnerability that enhances treatment response.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362407,1790193629,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":86,"file_id":87,"file_url":88,"file_type":89,"file_size":90,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":91,"language":92,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":93,"faqs":94,"seo_title":95,"seo_description":12,"update_tm":96,"read_time":97,"preview_page_count":33,"preview_urls":98},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Review  \nHigh-Grade Serous Ovarian Carcinoma in the Genomics Era: Current Applications, Challenges and Future Directions  \nMolly Elizabeth Lewis 1,2, Chiara Caricato 2, Hannah Leigh Roberts 3, Subhasheenee Ganesan 2, Nadia Amel Seksaf 1,2, Eleni Maniati 4,† and Michail Sideris 2,3, *,†  \nAcademic Editor: LuísLima  \nReceived: 20 December 2025  \nRevised: 1 February 2026  \nAccepted: 4 February 2026  \nPublished: 6 February 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 2AD, UK; [m.e.lewis@smd21.qmul.ac.uk](m.e.lewis@smd21.qmul.ac.uk) (M.E.L.); [n.a.seksaf@smd22.qmul.ac.uk](n.a.seksaf@smd22.qmul.ac.uk) (N.A.S.)  \n2 Wolfson’s Institute of Population Health, Queen Mary University of London, London EC1M 6BQ, UK; [c.caricato@qmul.ac.uk](c.caricato@qmul.ac.uk) (C.C.); [s.ganesan@qmul.ac.uk](s.ganesan@qmul.ac.uk) (S.G.)  \n3 Barts Health NHS Foundation Trust, London E14 5HJ, UK; [hannah.roberts38@nhs.net](hannah.roberts38@nhs.net)  \n4 Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK  \n* [Correspondence: m.sideris@qmul.ac.uk](Correspondence: m.sideris@qmul.ac.uk)  \n† These authors contributed equally to this work.  \nAbstract  \nHigh-grade serous ovarian carcinoma (HGSOC) is characterised by profound genomic instability and limited durable responses to standard therapy, leading to poor prognosis. The use of next-generation sequencing technologies has improved understanding of its molecular landscape, revealing consistent Tumour Protein p53 (TP53) mutations, homologous recombination defects, pathway alterations, and epigenetic dysregulation. Such genomic profiling now underpins the classification criteria between the ovarian cancer subtypes described by the Cancer Genome Atlas. Widespread chromosomal instability and pathogenic variants in multiple genes distinguish HGSOC from other subtypes of ovarian cancer and, further, from low-grade serous ovarian cancer. Importantly, the new-found understanding of the genomic landscape of HGSOC guides the use of platinum-based chemotherapies and Poly(ADP-ribose) Polymerase (PARP) inhibitors, with homologous recombination deficiency emerging as a cancer vulnerability that enhances treatment response. A combined multi-omics approach integrates transcriptomics, proteomics, metabolomics, and epigenomics to further the understanding of the characteristics, therapeutic targets and treatment resistance within HGSOC. Despite these advances, major challenges persist, including intratumoural heterogeneity and the poor diversity of genomic datasets. Artificial Intelligence (AI) technology, Clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing, neoantigen-guided immunotherapy and ovarian cancer vaccination indicate a promising future for genomics-guided interventions and support the integration of genomics within multi-omic approaches to improve HGSOC outcomes.  \nKeywords: high-grade serous ovarian carcinoma; genomics; BRCA; TP53; homologous recombination  \n1. Introduction  \nDuring 2022, ovarian cancer (OC) affected 324,398 women globally, with a mortality of 206,839 [1] . These figures are predicted to rise, reaching over 500,000 cases and over 350,000 deaths globally per annum by 2050 [2] .  \nOC presents with non-specific symptoms [3], and consequently, diagnosis is often made at an advanced stage [4–6] . This causes challenges in successful treatment [7] and  \nperpetuates the high mortality rate of 55% at 5 years [4,8] . Traditionally, initial diagnosis is made using imaging in combination with serum CA-125 before definitive diagnosis via surgery and biopsy [5,9] . Treatment approaches involve the use of a combination of radical cytoreductive surgery and platinum chemotherapy [5,6,10] .  \nHigh","cbCaipeYQO8G36TB","https://ap.wps.com/l/cbCaipeYQO8G36TB","pdf",649856,21,"English","# Introduction\n## Genomic Landscape of HGSOC","[{\"question\":\"What makes high-grade serous ovarian carcinoma (HGSOC) clinically challenging?\",\"answer\":\"HGSOC shows profound genomic instability and limited durable responses to standard therapy, which contributes to poor prognosis and high mortality.\"},{\"question\":\"How do next-generation sequencing technologies improve understanding of HGSOC?\",\"answer\":\"They reveal a detailed molecular landscape, including recurrent TP53 mutations, homologous recombination defects, pathway alterations, and epigenetic dysregulation that support subtype classification.\"},{\"question\":\"Which genomic features help guide treatment in HGSOC?\",\"answer\":\"Genomic profiling supports the use of platinum-based chemotherapy and PARP inhibitors, with homologous recombination deficiency functioning as a key vulnerability that enhances treatment response.\"}]","High-Grade Serous Ovarian Carcinoma in the Genomics Era - Current Applications, Challenges and Future Directions | PDF",1790147579,53,[99,103,107,111],{"page_no":22,"url":100,"width":101,"height":102},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8cd82fce3f2c7067742d11a4a0a36a66.webp",983,1390,{"page_no":26,"url":104,"width":105,"height":106},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bdd73f4c77c1d843172d1f5e5d37e89c.webp",982,1388,{"page_no":30,"url":108,"width":109,"height":110},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64a3857af371d6987fab964676650b19.webp",981,1387,{"page_no":33,"url":112,"width":113,"height":114},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b50bbe263a25387f6fc9110893cffc38.webp",980,1385,{"code":4,"msg":82,"data":116},[117,121,125,129,134,139,144,147,152,155,159],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":118,"show_sort_weight":119,"slug":120},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":122,"show_sort_weight":123,"slug":124},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":126,"show_sort_weight":127,"slug":128},"Exam",70,"exam",{"id":130,"doc_module":4,"doc_module_name":25,"category_name":131,"show_sort_weight":132,"slug":133},5,"Comic",60,"comic",{"id":135,"doc_module":4,"doc_module_name":25,"category_name":136,"show_sort_weight":137,"slug":138},6,"Technology",50,"technology",{"id":140,"doc_module":4,"doc_module_name":25,"category_name":141,"show_sort_weight":142,"slug":143},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":145,"slug":146},30,"research-report",{"id":148,"doc_module":4,"doc_module_name":25,"category_name":149,"show_sort_weight":150,"slug":151},9,"Religion & Spirituality",20,"religion-spirituality",{"id":150,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":150,"slug":154},"World Cup","world-cup",{"id":156,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":156,"slug":158},10,"Lifestyle","lifestyle",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":130,"slug":162},19,"General","general"]